A Member company developed one new non-systemic disinfection agent, neutralizing sars-cov-2 viruses (all mutants, too) in gastrointestinal tract. Majority of sever, fatal clinical cases are GI tract challenged.
It might be beneficial in prevention, prophylaxis and therapy of Covid-19 patients, and eventual virus contacts, too. This agent is a well established use antibiotic, (no dedicated antibiotic manufacturing line is needed).
Detail are available under NDA signed.